Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 Pogledi
• 07/18/23
0
0
Ugraditi
administrator
Pretplatnici
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari